Clinical prognostic factors and outcomes of essential thrombocythemia when transformed to myelodysplastic syndromes and acute myeloid leukemia

Leukemia Research
Yaman SuleimanLing Zhang

Abstract

Transformation of essential thrombocythemia (ET) to myelodysplastic syndromes or acute myeloid leukemia is infrequent, comprising 1-5% of cases with dismal clinical outcome. Studies on prognosis in ET patients with leukemic transformation are limited. The large cohort included 40 patients (1990-2014) with ET transformation (median age of 59 years, M:F of 1:1). Median time from ET diagnosis to transformation was 76 months (26-481) with median follow-up time of 15 years. Advanced age, myelofibrosis (grade 2-3), and leukocytosis at the time of transformation were associated with inferior OS from transformation (p<0.05). Given rarity of the clinical scenario, multicenter efforts are encouraged.

References

Jan 20, 2000·Baillière's Clinical Haematology·A J BenchA R Green
Jan 13, 2001·Mayo Clinic Proceedings·A TefferiH C Hoagland
Nov 16, 2004·The American Journal of Medicine·Francesco PassamontiMario Lazzarino
Jul 8, 2005·The New England Journal of Medicine·Claire N HarrisonUNKNOWN United Kingdom Medical Research Council Primary Thrombocythemia 1 Study
Feb 25, 2009·European Journal of Haematology·Naseema GangatAlexandra P Wolanskyj
Apr 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter J CampbellAnthony R Green
Nov 26, 2010·Blood·Philip A BeerAnthony R Green
Dec 12, 2013·The New England Journal of Medicine·Thorsten KlampflRobert Kralovics
Dec 12, 2013·The New England Journal of Medicine·J NangaliaA R Green
Sep 6, 2014·Best Practice & Research. Clinical Haematology·Magnus BjörkholmÅsa Rangert Derolf
Dec 23, 2014·Future Oncology·Vijaya Raj Bhatt

❮ Previous
Next ❯

Citations

Apr 5, 2018·Leukemia & Lymphoma·Lise-Marie MollardJean-Christophe Ianotto
May 5, 2018·Experimental and Therapeutic Medicine·Yan-Bo NieXue-Lan Zuo

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.